Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
Salt Lake City – BioFire Defense, LLC has been awarded the Next Generation Diagnostic System (NGDS) Technology Development contract by the U.S. Department of Defense after 12 months of competitive prototyping.
The eight-year $240 million-biodefense program is managed by the Joint Program Executive Office’s Medical Countermeasure Systems (JPEO MCS) office. The NGDS program will expand BioFire’s FilmArray diagnostic menu by developing biothreat test capabilities for use across all four branches of the Department of Defense.
“This is a fantastic opportunity to deliver the most cutting-edge diagnostic system to our warfighter,” said Kirk Ririe, CEO of BioFire Defense.
The NGDS program will develop and deliver the new standard of biowarfare detection to the US Department of Defense, replacing the current Joint Biologic Agent Identification and Diagnostic System (JBAIDS). With the dual role FilmArray platform, the Department of Defense will be able to detect bioterror pathogens, as well as run the full suite of diagnostic test panels available for the system, including respiratory and blood culture test panels. Other options in the contract include additional test panel development and platform hardening for improved ruggedness.